Effect of single point mutations of the human tachykinin NK1 receptor on antagonist affinity

被引:19
|
作者
Lundstrom, K
Hawcock, AB
Vargas, A
Ward, P
Thomas, P
Naylor, A
机构
[1] GLAXO WELLCOME RES & DEV LTD,MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND
[2] GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND
关键词
Semliki Forest virus system; tachykinin NK1 receptor; mutagenesis; site-directed; binding assays; functional coupling;
D O I
10.1016/S0014-2999(97)01226-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Molecular modelling and site-directed mutagenesis were used to identify eleven amino acid residues which may be involved in antagonist binding of the human tachykinin NK1 receptor. Recombinant receptors were expressed in mammalian cells using the Semliki Forest virus system. Wild type and mutant receptors showed similar expression levels in BHK and CHO cells, verified by metabolic labelling Binding affinities were determined for a variety of tachykinin NK1 receptor antagonists in SFV-infected CHO cells. The binding affinity for GR203040, CP 99,994 and CP 96,345 was significantly reduced by mutant Q165A. The mutant F268A significantly reduced the affinity for GR203040 and CP 99,994 and the mutant H197A had reduced affinity for CP 96,345. All antagonists seemed to bind in a similar region of the receptor, but do not all rely on the same binding site interactions. Functional coupling to G-proteins was assayed by intracellular Ca2+ release in SFV-infected CHO cells. The wild type receptor and all mutants except A162L and F268A responded to substance P stimulation. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 50 条
  • [41] Gly(166) in the NK1 receptor regulates tachykinin selectivity and receptor conformation
    Ciucci, A
    Palma, C
    Riitano, D
    Manzini, S
    Werge, TM
    FEBS LETTERS, 1997, 416 (03) : 335 - 338
  • [42] Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion
    Hawcock, AB
    Beresford, IJM
    Marshall, FH
    Hagan, RM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (01) : 163 - 171
  • [43] Broad spectrum antiemetic effects of CP-122,721, a tachykinin NK1 receptor antagonist, in ferrets
    Gonsalves, S
    Watson, J
    Ashton, C
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 305 (1-3) : 181 - 185
  • [44] Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist
    Cirillo, R
    Astolfi, M
    Conte, B
    Lopez, G
    Parlani, M
    Terracciano, R
    Fincham, CI
    Manzini, S
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 341 (2-3) : 201 - 209
  • [45] The tachykinin NK1 receptor.: Part II:: distribution and pathophysiological
    Quartara, L
    Maggi, CA
    NEUROPEPTIDES, 1998, 32 (01) : 1 - 49
  • [46] Direct evidence for the interaction of neurokinin A with the tachykinin NK1 receptor in tissue
    Bremer, AA
    Tansky, MF
    Wu, MY
    Boyd, ND
    Leeman, SE
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 423 (2-3) : 143 - 147
  • [47] Anti-emetic potential of tachykinin NK1 receptor antagonists
    J A RUDD
    M P NGAN
    M K WAI
    Acta Pharmacologica Sinica, 1999, (07) : 96 - 96
  • [48] The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret
    Singh, L
    Field, MJ
    Hughes, J
    Kuo, BS
    SumanChauhan, N
    Tuladhar, BR
    Wright, DS
    Naylor, RJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 321 (02) : 209 - 216
  • [49] GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity
    Gardner, CJ
    Armour, DR
    Beattie, DT
    Gale, JD
    Hawcock, AB
    Kilpatrick, GJ
    Twissell, DJ
    Ward, P
    REGULATORY PEPTIDES, 1996, 65 (01) : 45 - 53
  • [50] Increased tachykinin NK1 receptor immunoreactivity in the prefrontal cortex in schizophrenia
    Tooney, PA
    Crawter, VC
    Chahl, LA
    BIOLOGICAL PSYCHIATRY, 2001, 49 (06) : 523 - 527